Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of Nx-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart.

Trial Profile

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of Nx-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2018

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Registrational
  • Sponsors Nymox Pharmaceutical Corporation
  • Most Recent Events

    • 22 May 2018 According to a Nymox Pharmaceutical Corporation media release, results from this trial were Presented and Discussed at American Urological Association Annual Meeting 2018.
    • 01 Mar 2018 According to a Nymox Pharmaceutical Corporation media release, results from this trial will be presented at the Annual Meeting of the American Urological Association in Mar 2018.
    • 05 Feb 2018 According to a Nymox Pharmaceutical Corporation media relase, company will submitt an NDA for Fexapotide Triflutate for the treatment of BPH to the US FDA in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top